We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Provides New Financial Perks for Large Orphan Drugmakers
EMA Provides New Financial Perks for Large Orphan Drugmakers
In a boost for big pharma, the European Medicines Agency raised the fee-reduction rate for non-small and medium-sized enterprises seeking assistance on adult-only protocol from 40 percent to 75 percent, effective Jan. 1.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor